{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:49:16Z","timestamp":1790470156084,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T00:00:00Z","timestamp":1488412800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","exphem.org","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.exphem.2016.11.005","type":"journal-article","created":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T13:19:12Z","timestamp":1482499152000},"page":"13-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Preclinical approaches in chronic myeloid leukemia: from cells to systems"],"prefix":"10.1016","volume":"47","author":[{"given":"Cassie J.","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa L.","family":"Holyoake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2016.11.005_bib1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ardp.19963290707","article-title":"Phenylamino-pyrimidine (PAP) derivatives: A new class of potent and selective inhibitors of protein kinase C (PKC)","volume":"329","author":"Zimmermann","year":"1996","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.exphem.2016.11.005_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/978-1-4939-4011-0_14","article-title":"High-throughput screening of tyrosine kinase inhibitor resistant genes in CML","volume":"1465","author":"Ma","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.exphem.2016.11.005_bib3","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1186\/1471-2407-12-303","article-title":"Wnt\/\u03b2-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia","volume":"12","author":"Corr\u00eaa","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.exphem.2016.11.005_bib4","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/sj.leu.2403749","article-title":"Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations","volume":"19","author":"Andersson","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2016.11.005_bib5","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0145-2126(94)90103-1","article-title":"Leukemia cell lines: in\u00a0vitro models for the study of chronic myeloid leukemia","volume":"18","author":"Drexler","year":"1994","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2016.11.005_bib6","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib7","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","article-title":"The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells","volume":"90","author":"Deininger","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","author":"Druker","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2016.11.005_bib9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nature18288","article-title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","volume":"534","author":"Abraham","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2016.11.005_bib10","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic reprogramming sensitizes CML stemc to combined EZH2 and tyrosine kinase inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2016.11.005_bib11","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","article-title":"BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance","volume":"108","author":"Koptyra","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib13","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jnci\/djk150","article-title":"Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells","volume":"99","author":"Jiang","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.exphem.2016.11.005_bib14","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1002\/cncr.27506","article-title":"Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy","volume":"118","author":"Defina","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2016.11.005_bib15","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/leu.2013.19","article-title":"Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients","volume":"27","author":"Mustjoki","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2016.11.005_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in\u00a0vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib17","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib18","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"J\u00f8rgensen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib19","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2016.11.005_bib21","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib22","doi-asserted-by":"crossref","first-page":"724360","DOI":"10.1155\/2013\/724360","article-title":"Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells","volume":"2013","author":"Hamad","year":"2013","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.exphem.2016.11.005_bib23","article-title":"The chronic myeloid leukaemia stem cell: Stemming the tide of persistence","author":"Holyoake","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jnci\/djt006","article-title":"Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex","volume":"105","author":"Chen","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.exphem.2016.11.005_bib25","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Neviani","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2016.11.005_bib26","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in\u00a0vitro and in\u00a0vivo","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib27","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1172\/JCI79196","article-title":"Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells","volume":"126","author":"Zhang","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2016.11.005_bib28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2016.11.005_bib29","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1002\/stem.1748","article-title":"The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors","volume":"32","author":"Pellicano","year":"2014","journal-title":"Stem Cells"},{"key":"10.1016\/j.exphem.2016.11.005_bib30","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2016.11.005_bib31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2016.11.005_bib32","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2016.11.005_bib33","doi-asserted-by":"crossref","first-page":"25476","DOI":"10.1038\/srep25476","article-title":"Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia","volume":"6","author":"Irvine","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.exphem.2016.11.005_bib34","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2016.11.005_bib35","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2016.11.005_bib36","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1172\/JCI66129","article-title":"Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival","volume":"124","author":"Chen","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2016.11.005_bib37","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/stem.2347","article-title":"Autophagy proteins ATG5 and ATG7 are essential for the maintenance of human CD34(+) hematopoietic stem-progenitor cells","volume":"34","author":"Gomez-Puerto","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.exphem.2016.11.005_bib38","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.exphem.2016.11.005_bib39","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/j.1460-2075.1990.tb08212.x","article-title":"bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice","volume":"9","author":"Elefanty","year":"1990","journal-title":"EMBO J"},{"key":"10.1016\/j.exphem.2016.11.005_bib40","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1073\/pnas.87.17.6649","article-title":"Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR\/ABL","volume":"87","author":"Kelliher","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2016.11.005_bib41","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity","volume":"189","author":"Li","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2016.11.005_bib42","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood-2003-12-4369","article-title":"Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis","volume":"105","author":"Koschmieder","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib43","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1182\/blood-2009-04-215376","article-title":"BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells","volume":"115","author":"Schemionek","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib44","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/leu.2011.366","article-title":"Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML","volume":"26","author":"Schemionek","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2016.11.005_bib45","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood.V92.4.1390","article-title":"The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic\/severe combined immunodeficiency mice reflect the phase of the donor's disease: An in\u00a0vivo model of chronic myelogenous leukemia biology","volume":"92","author":"Dazzi","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib46","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood.V91.7.2406","article-title":"High level engraftment of NOD\/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase","volume":"91","author":"Wang","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib47","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1073\/pnas.94.10.5320","article-title":"Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice","volume":"94","author":"Bhatia","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2016.11.005_bib48","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib49","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/sj.leu.2403649","article-title":"Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease","volume":"19","author":"Eisterer","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2016.11.005_bib50","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nature19801","article-title":"T-Cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments","volume":"538","author":"Hawkins","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2016.11.005_bib51","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1182\/blood-2016-05-719021","article-title":"Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches","volume":"128","author":"Antonelli","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib52","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/978-1-4939-3661-8_13","article-title":"Chronic myeloid leukemia (CML) mouse model in translational research","volume":"1438","author":"Peng","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.exphem.2016.11.005_bib53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-4939-4011-0_2","article-title":"Induction of chronic myeloid leukemia in mice","volume":"1465","author":"Zhang","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.exphem.2016.11.005_bib54","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1128\/MCB.20.4.1149-1161.2000","article-title":"Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder","volume":"20","author":"Hao","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.exphem.2016.11.005_bib55","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood-2015-06-653006","article-title":"Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1","volume":"127","author":"Gu","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib56","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2014-01-547943","article-title":"IKK-dependent activation of NF-\u03baB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1","volume":"123","author":"Hsieh","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib57","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1172\/JCI85239","article-title":"Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia","volume":"126","author":"Jin","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2016.11.005_bib58","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/sj.leu.2404151","article-title":"The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib","volume":"20","author":"Miething","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2016.11.005_bib59","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2006-10-054098","article-title":"Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells","volume":"110","author":"Peng","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib60","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","article-title":"Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells","volume":"121","author":"Bolton-Gillespie","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib61","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2016.11.005_bib62","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","article-title":"Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia","volume":"21","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2016.11.005_bib63","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1084\/jem.20141661","article-title":"A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression","volume":"212","author":"Giotopoulos","year":"2015","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2016.11.005_bib64","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2001-12-0207","article-title":"NOD\/SCID\/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells","volume":"10","author":"Ito","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib65","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells","volume":"174","author":"Shultz","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2016.11.005_bib66","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2010-08-301507","article-title":"Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte\u2013macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2R\u03b3(null) humanized mice","volume":"117","author":"Billerbeck","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib67","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nbt.2858","article-title":"Development and function of human innate immune cells in a humanized mouse model","volume":"32","author":"Rongvaux","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2016.11.005_bib68","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.stemcr.2014.12.005","article-title":"Nonirradiated NOD,B6.SCID Il2r\u03b3\u2013\/\u2013 Kit(W41\/W41) (NBSGW) mice support multilineage engraftment of human hematopoietic cells","volume":"4","author":"McIntosh","year":"2015","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.exphem.2016.11.005_bib69","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/leu.2016.108","article-title":"Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model","volume":"30","author":"Sontakke","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2016.11.005_bib70","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-1-4939-4011-0_15","article-title":"Biological analysis of human CML stem cells: Xenograft model of chronic phase human chronic myeloid leukemia","volume":"1465","author":"Abraham","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.exphem.2016.11.005_bib71","doi-asserted-by":"crossref","first-page":"298ra119","DOI":"10.1126\/scitranslmed.aab1740","article-title":"Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling","volume":"7","author":"Riether","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2016.11.005_bib72","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib73","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Chronic Myelogenous Leukemia Version 4.2015. NCCN.org."},{"key":"10.1016\/j.exphem.2016.11.005_bib74","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","article-title":"A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib","volume":"115","author":"McWeeney","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.11.005_bib75","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2016.11.005_bib76","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(12)70474-6","article-title":"Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: An exploratory proof-of-mechanism study","volume":"13","author":"Ray-Coquard","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2016.11.005_bib77","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2016.11.005_bib78","unstructured":"Chen T, Mosbergen R, Korn O, Wells CA. Stemformatics: A visualisation platform for well curated biological sequence data. Single Cell Genomics 2016. At Wellcome Genome Campus, Hinxton, Cambridge, UK,\u00a02016."},{"key":"10.1016\/j.exphem.2016.11.005_bib79","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2016.11.005_bib80","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nbt.2530","article-title":"Heterogeneity of tumor-induced gene expression changes in the human metabolic network","volume":"31","author":"Hu","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2016.11.005_bib81","doi-asserted-by":"crossref","first-page":"rs6","DOI":"10.1126\/scisignal.2003573","article-title":"Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells","volume":"6","author":"Casado","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.exphem.2016.11.005_bib82","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X16307500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X16307500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T05:34:14Z","timestamp":1601271254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X16307500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":82,"alternative-id":["S0301472X16307500"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2016.11.005","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical approaches in chronic myeloid leukemia: from cells to systems","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2016.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}